Healthcare & Biotech

SHERIDAN, WYOMING - June 18, 2025 - Dentsply Sirona and High Point University (HPU) have announced a long-term collaboration that marks a significant step forward in the evolution of dental education, pairing cutting-edge technology with an innovative academic model designed to prepare practice-ready dental professionals.

Equipping the Next Generation with Practice-Ready Skills

The partnership, launching in summer 2025, will see Dentsply Sirona provide advanced equipment and digital solutions to HPU's Workman School of Dental Medicine. This includes fully-integrated Intego Treatment Centers, Primescan intraoral scanners, Primemill units, Primeprint 3D printing solutions, and CEREC software-technologies already shaping modern clinical environments.

Through this initiative, students will gain hands-on training in real-world settings, benefiting from:

SHERIDAN, WYOMING - June 18, 2025 - Dentsply Sirona has launched a pioneering CAD/CAM zirconia abutment block that uniquely merges high strength with superior esthetics for implant-based restorations. The CEREC Cercon 4D™ Multidimensional Zirconia Abutment Block debuts alongside the new Calibra® Abutment Resin Cement, delivering a streamlined, high-performance chairside workflow for dental professionals.

Innovative layering for natural-looking implant restorations

Unlike traditional multilayer zirconia blocks built with flat horizontal layers, CEREC Cercon 4D™ uses a proprietary 3-dimensional layering process. Its dome-shaped dentin core contains increased opacity and pigment, surrounded by a more translucent enamel layer-closely mimicking the natural composition of teeth. The result is an esthetic solution that effectively masks TiBases and integrates seamlessly with VITA® 1 shade matching.

The block offers:

SHERIDAN, WYOMING – June 16, 2025 – Roche has unveiled promising Phase III results for its immunotherapy Tecentriq® (atezolizumab) combined with lurbinectedin (Zepzelca®) in the treatment of extensive-stage small cell lung cancer (ES-SCLC), offering new hope for a patient population with few effective treatment options and historically poor survival outcomes.

The IMforte study demonstrated that this first-line maintenance regimen significantly improves both progression-free and overall survival compared to Tecentriq monotherapy. With a 46% reduction in the risk of disease progression or death and a 27% reduction in overall mortality, the trial marks a notable advancement in the treatment of this aggressive cancer.

Practice-Changing Potential for a Hard-to-Treat Cancer

SHERIDAN, WYOMING – June 12, 2025 – Genentech, a biotechnology powerhouse and subsidiary of Roche, has confirmed the layoff of 143 employees at its South San Francisco headquarters, marking the latest phase in a year-long operational reshaping. The company disclosed the reduction via a Worker Adjustment and Retraining Notification (WARN), with job terminations set to take effect on July 14.

This development follows a sequence of strategic shifts initiated by Roche in 2024 aimed at aligning Genentech’s structure with evolving R&D and market priorities. While challenging for employees, these steps underscore Roche’s ongoing commitment to innovation, cost efficiency, and portfolio realignment.

Restructuring in Response to Strategic Business Reviews

SHERIDAN, WYOMING – June 12, 2025 – In a strategic move signaling regulatory reform and modernization, FDA Commissioner Marty Makary and CBER Director Vinay Prasad have outlined a new four-year roadmap for the agency in The Journal of the American Medical Association (JAMA). Their article, “Priorities for a New FDA,” introduces a reform-focused agenda that emphasizes accelerated drug approval timelines, generative AI implementation, and a renewed focus on cost transparency and public health outcomes.

Accelerating Approvals While Guarding Independence

SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling final overall survival data from its phase III INAVO120 study, showing that the Itovebi™ (inavolisib)-based regimen reduces the risk of death by more than 30% in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The findings were presented at the 2025 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.

First PI3K Inhibitor to Prolong Survival in This Breast Cancer Subtype

The INAVO120 trial demonstrated that Itovebi, when combined with palbociclib and fulvestrant, achieved a median overall survival (OS) of 34.0 months compared to 27.0 months for the control group receiving palbociclib and fulvestrant alone. This represents a statistically significant and clinically meaningful improvement (HR=0.67; p=0.0190).

SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling new data from its ongoing FENopta open-label extension study, confirming that its investigational therapy fenebrutinib continues to provide sustained disease suppression in patients with relapsing multiple sclerosis (RMS) for up to two years.

The 96-week results presented at the CMSC Annual Meeting in Phoenix highlight fenebrutinib’s potential as a first-in-class reversible Bruton’s tyrosine kinase (BTK) inhibitor in the multiple sclerosis space. This development is poised to influence treatment paradigms, particularly as Phase III results approach later this year.

Sustained Disease Control With No Observed Disability Progression

SHERIDAN, WYOMING – May 27, 2025 – Roche has received a significant endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which issued a positive opinion for Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant. This recommendation positions Roche to offer a first-line treatment solution for adult patients with PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer—an area with limited current treatment options.

This development is underpinned by data from the phase III INAVO120 study, which demonstrated that the Itovebi-based regimen more than doubled progression-free survival compared to the standard treatment alone. The recommendation marks a key milestone toward potential European Commission approval, with broader implications for treatment standards across the region.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

This joint initiative is poised to establish SBX as a clinical mainstay in neonatal intensive care units (NICUs), helping identify genetic disorders in newborns with unprecedented speed and precision. It also positions both organizations to lead in delivering fast, scalable, and cost-efficient genomic insights that could redefine diagnostic and therapeutic practices.

Targeting Transformational Impact in Clinical Genomics

SHERIDAN, WYOMING – May 27, 2025 – Roche has unveiled compelling two-year follow-up data from its pivotal phase III STARGLO trial, reinforcing the long-term clinical value of Columvi® (glofitamab) in combination with chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The results underscore the strategic impact of Roche’s bispecific antibody pipeline in addressing aggressive hematologic malignancies with limited treatment options.

Landmark Survival Benefit in R/R DLBCL

The updated STARGLO data show a 40% improvement in overall survival for patients treated with Columvi plus GemOx (gemcitabine and oxaliplatin), compared to the control arm receiving MabThera®/Rituxan® (rituximab) with GemOx. Notably, the median overall survival for the Columvi arm was not reached, versus 13.5 months in the comparator group.

Further findings demonstrated: